Bank Hapoalim Announces First Quarter 2014 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Bank Hapoalim Announces First Quarter 2014 Financial Results

Net Profit totaled NIS 753 million
Return on Equity of 10.7%
Basel 3 Tier 1 Capital rose to 9.4%
Cash Dividend Payout of NIS 106 million to be paid from First Quarter 2014 Net Profit

TEL AVIV, Israel, May 22, 2014 (GLOBE NEWSWIRE) -- Bank Hapoalim (TASE: POLI ) (ADR:BKHYY), Israel's leading financial group, today announced financial results for the first quarter ended  March 31, 2014.

First Quarter 2014 Financial Highlights:  

  • Net profit totaled NIS 753 million compared with a profit of NIS 621 million in the same quarter last year.
     
  • Return on equity reached 10.7%, compared with 9.5% in the same quarter last year.
     
  • Tier 1 Capital Ratio, in Basel 3 terms , stood at 9.44% at the end of the first quarter 2014, compared with 9.15% at January 1, 2014.
     
  • Total Capital Ratio, in Basel 3 terms , as at March 31, 2014 was 14.96% compared with 14.68% on January 1, 2014.
     
  • Quarterly Dividend - The Bank's Board of Directors approved the continuation of the quarterly cash dividend distribution, at a rate of approximately 15% of net profit, from its first quarter 2014 earnings in the amount of NIS 106 million.

Main developments in the financial statements for the first quarter of 2014:

Profit from regular financing activity totaled NIS 1,795 million in the first quarter of 2014, up from a profit of NIS 1,773 million in the same quarter last year.

The financial margin from regular activity stood at 2.1% in the first quarter of 2014, similar to the same quarter last year.

Provision for credit losses in the first quarter of 2014 recorded income of NIS 15 million, compared with an expense of NIS 257 million in the same quarter last year.

Fees and other income totaled NIS 1,299 million in the first quarter of 2014 compared with NIS 1,287 million in the same quarter last year, an increase of 0.9%.

Operating and other expenses totaled NIS 2,156 million in the first quarter of 2014 compared with NIS 2,135 in the same quarter last year.

Dividend declared - The Bank's Board of Directors approved the continuation of the quarterly cash dividend distribution and declared a dividend with respect to the first quarter 2014 profits, of approximately NIS 106 million, which amounts to 8 agorot per share. The record date is May 29, 2014 and the date of payment is June 12, 2014.

Contribution to the community - The Bank's employees are involved in a varied and extensive range of community-oriented activities that take the form of social involvement, monetary donations, and large-scale volunteer activities. Bank Hapoalim's community-oriented activity during the first quarter of 2014 was expressed in a financial value of approximately NIS 18 million.

Developments in Balance Sheet Items:

The consolidated balance sheet as at March 31, 2014 totaled NIS 376.9 billion, compared with NIS 380.2 billion at the end of 2013, a decrease of 0.9%.

Net Credit to the public totaled NIS 250.2 billion, compared with NIS 251.6 billion at the end of 2013, a decrease of 0.5% mainly as a result of a decrease in corporate credit offset by an increase in retail, small business, and commercial credit.

Credit to Retail customers totaled NIS 102.0 billion compared with NIS 100.4 billion at the end of 2013, an increase of 1.5%. This includes consumer credit which totaled  NIS 32.3 billion compared with NIS 31.4 billion at the end of 2013, an increase of 2.6%. Mortgages totaled NIS 58.4 billion compared with NIS 57.9 billion at the end of 2013, an increase of 0.9%.

Credit to Small Businesses totaled NIS 26.7 billion compared with NIS 26.2 billion at the end of 2013, an increase of 1.9%.

Credit to the Commercial segment totaled NIS 31.3 billion compared with NIS 31.1 billion at the end of 2013, an increase of 0.4%.

Deposits from the public totaled NIS 276.0 billion compared with NIS 276.5 billion at the end of 2013, a decrease of 0.2%, mainly a result of a shift in customers' investment preferences.

Shareholders' Equity totaled NIS 29.9 billion as at March 31, 2014, compared with NIS 29.1 billion at the end of 2013, an increase of 2.7%.

Conference Call Information

Bank Hapoalim will host a conference call as well as a slide presentation webcast today to review the First Quarter 2014 financial results at 10:00 a.m. U.S. Eastern Time / 3:00 p.m. UK Time / 5:00 p.m. Israel Time.

To access the call, please dial: 1-888-281-1167 in the U.S. and 1-866-485-2399 in Canada or (972) 3-9180685 for international participants. No password is required. The presentation slides, earnings release and the First Quarter 2014 financial statements are available at the Bank's website, www.bankhapoalim.com , under Investor Relations, Financial Information.

A replay of the conference call will be available beginning at approximately 1:00 p.m. U.S. Eastern Time / 6:00 p.m. UK Time / 8:00 p.m. Israel Time on Thursday, May  22, 2014 through 1:00 p.m. Eastern Time / 6:00 p.m. UK Time / 8:00 p.m. Israel Time on Thursday May 29, 2014 by telephone at (972) 3-9255918 (international).

The webcast replay will also be available by audio playback on the Bank Hapoalim website at www.bankhapoalim.com , under Investor Relations, Financial Information.

About Bank Hapoalim

Bank Hapoalim is Israel's leading financial group. In Israel, the Bank Hapoalim Group has over 260 branches, eight regional business centers, a network of 22 business branches and specialized industry relationship managers for major corporate customers.

The Bank Hapoalim Group includes Isracard Ltd, Israel's leading credit card company as well as financial companies involved in investment banking, trust services and portfolio management.

Internationally, Bank Hapoalim operates through branches, subsidiaries and representative offices, in North America, Latin America, Europe, the Far East, and Turkey. In these markets, the Bank is engaged in trade, corporate finance, private banking and retail banking.

Bank Hapoalim is listed on the Tel Aviv Stock Exchange. In addition, a Level-1 ADR is traded "over-the-counter" in New York.

For more information about Bank Hapoalim, please visit us online at www.bankhapoalim.com .

Principal Data of the Bank Hapoalim Group   (NIS millions)
     
Profit and Profitability   For the three months ended
  March 31,
2014
Dec. 31,
2013
Sept. 30,
2013
June 30,
2013
March 31,
2013
Net financing income* 2,056 2,073 2,117 2,176 2,057
Fees and other income 1,299 1,394 1,278 1,282 1,287
Total income 3,355 3,467 3,395 3,458 3,344
Provision (income) for credit losses (15) (59) 375 301 257
Operating and other expenses 2,156 2,562 2,133 2,135 2,135
Net profit attributed to shareholders of the Bank 753 651 653 655 621
 
  March 31,
2014
Dec. 31,
2013
Sept. 30,
2013
June 30,
2013
March 31,
2013
Balance Sheet – Principal Data          
Total balance sheet 376,867 380,246 374,216 378,483 370,317
Net credit to the public 250,232 251,600 249,341 247,120 247,782
Securities 65,333 60,912 60,998 61,137 59,461
Deposits from the public 276,014 276,525 269,632 274,601 265,297
Bonds and subordinated notes 31,314 33,980 34,819 35,874 36,222
Shareholders' equity 29,855 29,060 28,391 27,808 27,279
Net total problematic credit risk** 14,205 16,279 13,870 13,264 13,561
Of which: net impaired balance sheet debts** 6,305 6,817 6,624 7,030 6,856
           
 
Main Financial Ratios March 31,
2014
Dec. 31,
2013
Sept. 30,
2013
June 30,
2013
March 31,
2013
Net loan to deposit ratio 90.7% 91.0% 92.5% 90.0% 93.4%
Net loan to deposit ratio including bonds and subordinated notes 81.4% 81.0% 81.9% 79.6% 82.2%
Shareholders' equity to total assets 7.9% 7.6% 7.6% 7.3% 7.4%
Common equity Tier 1 capital according to Basel 3 9.4%        
Total capital according to Basel 3 15.0%        
Ratio of core capital to risk-adjusted assets according to Basel 2 --  9.4% 9.3% 9.2% 9.1%
Ratio of total capital to risk-adjusted assets according to Basel 2 --  15.6% 15.7% 15.7% 15.6%
Financing margin from regular activity (1)(2) 2.09% 2.13% 2.20% 2.16% 2.07%
Cost-income ratio (5) 64.3% 61.2% 62.8% 61.7% 63.8%
Total income to assets (3) 3.6% 3.8% 3.6% 3.7% 3.7%
Total expenses to assets (4) 2.3% 2.8% 2.3% 2.3% 2.3%
Provision (income) for credit losses as a percentage of the average recorded balance of credit to the public (1) (0.02%) (0.09%) 0.59% 0.48% 0.41%
Net return of profit attributed to shareholders of the Bank on equity (1) 10.7% 9.4% 9.6% 9.9% 9.5%
Basic net earnings per share in NIS attributed to shareholders of the Bank 0.57 0.49 0.50 0.50 0.47
           
* Net financing income includes net interest income and non-interest income (expenses).
** Net of the individual allowance, the allowance according to the extent of arrears, and the collective allowance in respect of problematic credit risk.
(1) Calculated on an annualized basis.
(2) Financing profit from regular activity (see the Board of Directors' report, in the section Profit and Profitability – Development of Financing Profit) is divided by total financial assets after allowance for credit losses, net of non-interest bearing balances in respect of credit cards.
(3) Total income divided by the average balance of total assets.
(4) Total operating and other expenses, divided by the balance of total average assets.
(5) Does not include expenses for efficiency plans.

For further information please contact: Press: Ofra Preuss, Bank's Spokesperson Tel: +972-3-567-3635; Fax: +972-3-567-3500 Investors: Effie Werber, Head of Investor Relations Tel. +972-3-567-3440; Fax: +972-3-5673470

Scroll down for more posts ▼

Top 10 Most Recent News Articles

RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 115

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 134

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 175

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 194

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Updated Category News Views 94

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 361

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 279

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Ping An's Bold Green Moves Ahead of APEC 2026

Updated Category News Views 175

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Continue Reading
Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 151

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
Love Business Group Helps SMEs Navigate Broadband Choices

Updated Category News Views 88

Understanding Broadband Needs for UK SMEs When you're knee-deep in running a small biz in the UK, sorting out your broadband needs can feel like sifting through a thousand-piece puzzle. Enter Love Business Group, getting a nod of recognition for being the SME knight in shining armor. Aimed at businesses of all sizes, they've been pegged by Expert Consumers for helping...

Continue Reading

Top 5 Most Recently Viewed Articles

AXIS Capital Leadership Changes Enhance Global Operations

Updated Category News Views 115

AXIS Capital Leadership Appointments for Irish Entities AXIS Capital Holdings Limited (NYSE: AXS) has taken significant steps to enhance its operational leadership. Recently, the company announced key leadership appointments for its Irish legal entities, AXIS Re SE ("ARe") and AXIS Specialty Europe SE ("ASE"). Both entities are based in Ireland and are regulated by the...

Continue Reading
AI Transformation and Market Growth in Office Supplies B2B Sector

Updated Category News Views 202

The global office stationery and supplies B2B market experienced a significant transformation driven by artificial intelligence and an uptick in business expansions. Back in 2024, the market was poised to grow by USD 20.5 billion from then to 2028, translating to a compound annual growth rate (CAGR) of 1.96%. The rising demand for environmentally friendly and recyclable...

Continue Reading
NewLake Capital Strengthens Board with Dina Rollman's Addition

Updated Category News Views 293

NewLake Capital Partners Welcomes Dina Rollman NewLake Capital Partners, Inc. (OTCQX: NLCP), a prominent provider of real estate capital to state-licensed cannabis operators, is excited to announce the recent appointment of Dina Rollman to its Board of Directors. This strategic move aims to bolster the company’s leadership as it continues to thrive in the evolving...

Continue Reading
Nasdaq Reports Surge in IPO Activity for 2025 to Date

Updated Category News Views 1069

Record Activity in Nasdaq's IPO Sphere for 2025 As the trading world gained momentum in 2025, Nasdaq showcased remarkable activity, welcoming 142 initial public offerings (IPOs) during the first half of the year. This impressive figure translated into a substantial capital raise of $19.2 billion, marking a significant resurgence in the IPO arena. Robust Listings and...

Continue Reading
Introducing ecoVerificado.com: A New Standard for Baby Diapers

Updated Category News Views 92

Revolutionizing Eco-Friendly Baby Diapers In an exciting development for the baby care industry, GreenCore Solutions Corp. has launched ecoVerificado.com, creating a brand new standard for sustainable private-label baby diapers. This initiative is a game changer for manufacturers in Latin America, enabling the production of premium ecological diapers without compromising...

Continue Reading